Tag: management

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc (OTC:RBGLY), UroGen Pharma Ltd. (NASDAQ:URGN), Red Cat Holdings, Inc. (NASDAQ: RCAT) and Fortrea Holdings Inc. (NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Dubai, UAE , June 16, 2025 (GLOBE NEWSWIRE) -- In a major leap toward redefining privacy in Web3, NullTrace officially announces the upcoming launch of its OTC marketplace (Phase 1 of Shadow DEX), AI dapp assistant & native privacy wallet, solidifying its position as the go-to privacy layer on Solana. As blockchain adoption grows and transparency becomes a double-edged sword, on-chain privacy is no longer optional—it’s critical infrastructure.

NullTrace offers a ZK-powered, full-stack privacy suite: stealth swaps, token mixers, private transfers and airdrops, and an untraceable cross-chain bridge. Its tools empower users with confidential custody, anonymous transfers, and unlinkable activity—all while maintaining decentralization and performance.

Privacy Without Compromise

Blockchain transparency has made wallet activity, trades, and airdrops fully public. This deters institutional adoption and exposes users to surveillance. NullTrace fixes this with stealth address infrastructure, encrypted balances, and zero-knowledge proofs—all native to Solana.

Key Offerings Include:

ZK Privacy Bridge: Enables unlinkable cross-chain value movement using stealth routing.

SPL Mixer: Native Solana mixer supporting SOL & SPL tokens, enabling encrypted transfers.

Privacy Airdrops: Distribute tokens to stealth addresses with zero exposure.

$NULL Token: Access tools, earn revshare, and participate in governance.

Protocol fees are shared with $NULL holders and partially burned, creating strong utility and alignment with growth.

What’s Coming Next

This announcement comes as NullTrace prepares to roll out two major privacy innovations:

Shadow DEX: A stealth orderbook DEX with encrypted matching and on-chain private settlement—ideal for OTC deals and DAO allocations.

Null Wallet: A fully integrated wallet optimized for stealth address management and shielded asset tracking.

AI Chat Assistant: Built into both web and Telegram interfaces, this guide helps users navigate complex privacy tools and protocols seamlessly.

Live Today

- SPL Mixer (SOL & tokens)

- Private Bridge (Solana-native)

- Stealth Airdrop Tool

- Revenue Sharing via $NULL

Coming in 2025

- Shadow DEX Phase 1

- Full AI Assistant Rollout

- Launch of Null Wallet

- EVM & Bitcoin Support

Final Word

NullTrace isn’t just building a mixer—it’s constructing the privacy foundation of Solana and Web3. With the upcoming launch of its privacy-native wallet and Shadow DEX, the protocol is delivering programmable, high-speed, trustless confidentiality to everyone—from retail users to DAOs and institutions.

Explore NullTrace:

Web App: https://nulltrace.xyz/

Docs: https://docs.nulltrace.xyz/

Twitter/X: https://x.com/nulltracebot

All Links: https://linktr.ee/nulltrace

Privacy isn’t a luxury. It’s infrastructure—and NullTrace is making it mainstream.

Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.

PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million. The Company anticipates that with this additional funding, PolyPid’s runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀.